Patents by Inventor Donna T. Ward

Donna T. Ward has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense modulation of MEKK4 expression
    Publication number: 20030144242
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK4. Methods of using these compounds for modulation of MEKK4 expression and for treatment of diseases associated with expression of MEKK4 are provided.
    Type: Application
    Filed: February 21, 2003
    Publication date: July 31, 2003
    Inventors: Donna T. Ward, William Gaarde, Brett P. Monia, Jacqueline Wyatt
  • Antisense modulation of ABC transporter MHC 1 expression
    Publication number: 20030134809
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of ABC transporter MHC 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding ABC transporter MHC 1. Methods of using these compounds for modulation of ABC transporter MHC 1 expression and for treatment of diseases associated with expression of ABC transporter MHC 1 are provided.
    Type: Application
    Filed: December 17, 2001
    Publication date: July 17, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Alexander H. Borchers, Donna T. Ward, Susan M. Freier
  • Antisense modulation of RECQL5 expression
    Publication number: 20030114412
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of RECQL5. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RECQL5. Methods of using these compounds for modulation of RECQL5 expression and for treatment of diseases associated with expression of RECQL5 are provided.
    Type: Application
    Filed: December 3, 2002
    Publication date: June 19, 2003
    Inventors: Donna T. Ward, Andrew T. Watt
  • Antisense modulation of EIF2C1 expression
    Publication number: 20030105042
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of EIF2C1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding EIF2C1. Methods of using these compounds for modulation of EIF2C1 expression and for treatment of diseases associated with expression of EIF2C1 are provided.
    Type: Application
    Filed: November 8, 2001
    Publication date: June 5, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Donna T. Ward, Andrew T. Watt
  • Antisense modulation of ribonuclease L expression
    Publication number: 20030100522
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of ribonuclease L. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding ribonuclease L. Methods of using these compounds for modulation of ribonuclease L expression and for treatment of diseases associated with expression of ribonuclease L are provided.
    Type: Application
    Filed: September 12, 2001
    Publication date: May 29, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Donna T. Ward, Andrew T. Watt
  • Antisense modulation of protein kinase R expression
    Publication number: 20030087855
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Protein Kinase R. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Protein Kinase R. Methods of using these compounds for modulation of Protein Kinase R expression and for treatment of diseases associated with expression of Protein Kinase R are provided.
    Type: Application
    Filed: September 13, 2001
    Publication date: May 8, 2003
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Donna T. Ward, Andrew T. Watt
  • Antisense modulation of RECQL5 expression
    Publication number: 20030083302
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of RECQL5. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RECQL5. Methods of using these compounds for modulation of RECQL5 expression and for treatment of diseases associated with expression of RECQL5 are provided.
    Type: Application
    Filed: September 9, 2002
    Publication date: May 1, 2003
    Inventors: Donna T. Ward, Andrew T. Watt
  • ANTISENSE INHIBITOR OF RECQL4 EXPRESSION
    Publication number: 20020142975
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of RECQL4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RECQL4. Methods of using these compounds for modulation of RECQL4 expression and for treatment of diseases associated with expression of RECQL4 are provided.
    Type: Application
    Filed: February 23, 2001
    Publication date: October 3, 2002
    Applicant: Isis Pharmaceuticals Inc.
    Inventors: Donna T. Ward, Andrew T. Watt
  • Antisense modulation of WRN expression
    Patent number: 6448080
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of WRN. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding WRN. Methods of using these compounds for modulation of WRN expression and for treatment of diseases associated with expression of WRN are provided.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: September 10, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Donna T. Ward, Andrew T. Watt
  • Antisense modulation of helicase-moi expression
    Patent number: 6444466
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of helicase-moi. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding helicase-moi. Methods of using these compounds for modulation of helicase-moi expression and for treatment of diseases associated with expression of helicase-moi are provided.
    Type: Grant
    Filed: May 10, 2001
    Date of Patent: September 3, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Donna T. Ward, Andrew T. Watt
  • Antisense inhibitor of RECQL4 expression
    Patent number: 6436706
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of RECQL4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RECQL4. Methods of using these compounds for modulation of RECQL4 expression and for treatment of diseases associated with expression of RECQL4 are provided.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: August 20, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Donna T. Ward, Andrew T. Watt
  • Antisense modulation of RIP2 expression
    Patent number: 6426221
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of RIP2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RIP2. Methods of using these compounds for modulation of RIP2 expression and for treatment of diseases associated with expression of RIP2 are provided.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: July 30, 2002
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Donna T. Ward, Lex M. Cowsert
  • Antisense modulation of RECQL2 expression
    Patent number: 6399378
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of RECQL2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding RECQL2. Methods of using these compounds for modulation of RECQL2 expression and for treatment of diseases associated with expression of RECQL2 are provided.
    Type: Grant
    Filed: March 1, 2001
    Date of Patent: June 4, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Donna T. Ward, Andrew T. Watt
  • Antisense inhibition of MEKK2 expression
    Patent number: 6287860
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK2. Methods of using these compounds for modulation of MEKK2 expression and for treatment of diseases associated with expression of MEKK2 are provided.
    Type: Grant
    Filed: January 20, 2000
    Date of Patent: September 11, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, William Gaarde, Donna T. Ward, Susan M. Freier, Jacqueline Wyatt
  • Antisense modulation of MEKK1 expression
    Patent number: 6168950
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK1. Methods of using these compounds for modulation of MEKK1 expression and for treatment of diseases associated with expression of MEKK1 are provided.
    Type: Grant
    Filed: July 23, 1999
    Date of Patent: January 2, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, William Gaarde, Donna T. Ward, Lex M. Cowsert
  • Antisense modulation of NCK-2 expression
    Patent number: 6165728
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of nck-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding nck-2. Methods of using these compounds for modulation of nck-2 expression and for treatment of diseases associated with expression of nck-2 are provided.
    Type: Grant
    Filed: November 19, 1999
    Date of Patent: December 26, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Donna T. Ward, Lex M. Cowsert
  • Antisense modulation of PI3 kinase p55 gamma expression
    Patent number: 6165790
    Abstract: Antisense compounds, compositions and methods are provided for inhibiting the expression of PI3 kinase p55 gamma. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PI3 kinase p55 gamma. Methods of using these compounds for inhibition of PI3 kinase p55 gamma expression and for treatment of diseases associated with expression of PI3 kinase p55 gamma are provided.
    Type: Grant
    Filed: November 3, 1999
    Date of Patent: December 26, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Alexander H. Borchers, Donna T. Ward, Lex M. Cowsert
  • Antisense modulation of Jun N-terminal kinase kinase-1 expression
    Patent number: 6010906
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Jun N-terminal Kinase Kinase-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Jun N-terminal Kinase Kinase-1. Methods of using these compounds for modulation of Jun N-terminal Kinase Kinase-1 expression and for treatment of diseases associated with expression of Jun N-terminal Kinase Kinase-1 are provided.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: January 4, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Donna T. Ward, Lex M. Cowsert